Filing Details

Accession Number:
0000929638-24-001536
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-04-22 16:00:41
Reporting Period:
2024-04-18
Accepted Time:
2024-04-22 16:00:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1314102 Eyepoint Pharmaceuticals Inc. EYPT Laboratory Analytical Instruments (3826) 262774444
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1583977 Cormorant Asset Management, Lp 200 Clarendon Street
52Nd Floor
Boston MA 02116
No No No No
1599214 Bihua Chen C/O Cormorant Asset Management, Lp
200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No No No
1618442 Cormorant Global Healthcare Master Fund, Lp 200 Clarendon Street
52Nd Floor
Boston MA 02116
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-04-18 395,244 $17.62 7,288,479 No 4 P Indirect See Footnote
Common Stock Acquisiton 2024-04-18 186,521 $18.90 7,475,000 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Footnotes
  1. Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
  2. Represents the weighted average sale price of Common Stock (the "shares") purchased in a series of open market transactions on the transaction date at prices ranging from $17.36 to $18.25 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the "SEC"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.
  3. Represents the weighted average sale right of the shares purchased in a series of open market transactions on the transaction date at prices ranging from $18.43 to $19.06 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.